Publications by authors named "Segolene Duran"

Claim this Profile
C
Corrigendum to "The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017" [Eur J Canc 145 (2021) 11-18].
Marc A Rodwin, Julien Mancini, Ségolène Duran, Anne-Céline Jalbert, Patrice Viens

Eur J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Marc A Rodwin, Julien Mancini, Ségolène Duran, Anne-Céline Jalbert, Patrice Viens

Eur J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer.
Renaud Sabatier, Emanuel Nicolas, Maria Paciencia, Annie-Pierre Jonville-Béra, Anne Madroszyk, Ségolène Duran

J Geriatr Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Sylvain Garciaz, Diane Coso, Frederic Peyrade, Sabine Fürst, Ségolène Duran

Hematol Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.
Djamel Mokart, Géraldine Slehofer, Jérôme Lambert, Antoine Sannini, Laurent Chow-Chine, Ségolène Duran

Intensive Care Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-management strategies adopted by breast cancer survivors to improve their adherence to tamoxifen.
Aline Sarradon-Eck, Isabelle Pellegrini, Rémy Largillier, Ségolène Duran, Agnès Tallet

Breast J· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
Jean El-Cheikh, Roberto Crocchiolo, Sabine Furst, Patrick Ladaique, Luca Castagna, Segolene Duran

Exp Hematol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study.
Jean El Cheikh, Luca Castagna, Ling Wang, Benjamin Esterni, Catherine Faucher, Segolene Duran

Hematol Oncol Stem Cell Ther· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination.
Ségolène Duran, Gilles Peytavin, Patrizia Carrieri, François Raffi, Jean-Luc Ecobichon

AIDS· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life after 1 year of highly active antiretroviral therapy.
Patrizia Carrieri, Bruno Spire, Ségolène Duran, Christine Katlama, Dominique Peyramond

J Acquir Immune Defic Syndr· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.
Bernard Masquelier, Gilles Peytavin, Catherine Leport, Cecile Droz, Ségolène Duran

J Infect Dis· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.
Bruno Spire, Ségolène Duran, Marc Souville, Catherine Leport, François Raffi

Soc Sci Med· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.
Vincent Le Moing, Geneviève Chêne, Catherine Leport, Charlotte Lewden, Ségolène Duran

Clin Infect Dis· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis